183,239 Shares in Evommune, Inc. $EVMN Purchased by Monashee Investment Management LLC

Monashee Investment Management LLC bought a new position in shares of Evommune, Inc. (NYSE:EVMN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 183,239 shares of the company’s stock, valued at approximately $3,137,000. Evommune makes up 1.8% of Monashee Investment Management LLC’s investment portfolio, making the stock its 21st biggest position. Monashee Investment Management LLC owned approximately 0.58% of Evommune at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Evommune during the fourth quarter worth about $34,000. TD Asset Management Inc purchased a new stake in shares of Evommune during the fourth quarter worth about $764,000. Capricorn Fund Managers Ltd purchased a new stake in shares of Evommune during the fourth quarter worth about $1,027,000. Goldman Sachs Group Inc. purchased a new stake in shares of Evommune during the fourth quarter worth about $1,056,000. Finally, Seven Grand Managers LLC purchased a new stake in shares of Evommune during the fourth quarter worth about $1,284,000.

Evommune Price Performance

NYSE:EVMN opened at $20.69 on Friday. The firm has a market capitalization of $745.11 million and a price-to-earnings ratio of -2.18. Evommune, Inc. has a 1 year low of $13.89 and a 1 year high of $33.20. The business has a 50 day simple moving average of $23.72 and a 200-day simple moving average of $22.20.

Evommune (NYSE:EVMN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. As a group, analysts expect that Evommune, Inc. will post -2.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director David E. Cohen sold 6,056 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $20.33, for a total value of $123,118.48. Following the completion of the sale, the director directly owned 17,609 shares of the company’s stock, valued at $357,990.97. This trade represents a 25.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kyle Carver sold 18,175 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $22.84, for a total value of $415,117.00. Following the completion of the sale, the chief financial officer directly owned 59,335 shares of the company’s stock, valued at $1,355,211.40. The trade was a 23.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 71,928 shares of company stock worth $1,624,145.

Analyst Ratings Changes

Several analysts recently issued reports on EVMN shares. Clear Str upgraded Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Morgan Stanley increased their price target on Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Oppenheimer began coverage on Evommune in a research note on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price target for the company. Wall Street Zen raised Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, Stifel Nicolaus began coverage on Evommune in a research note on Friday, May 1st. They set a “buy” rating and a $54.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $49.25.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.